Alpine Global Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Alpine Global Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,404	Closed	-$74.2K	–	269
2024 Q4	$74.2K	Buy	+24,404	New	+$106K	0.01%	198

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Alpine Global Management's RVNC Position: Q1 2025 in Review

Alpine Global Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 24,404 shares — an estimated $74.2K sold.

Alpine Global Management first reported a position in RVNC in Q4 2024 and held it in 1 quarter. The position peaked at $74.2K in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Alpine Global Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Alpine Global Management sold 24,404 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $74.2K.
Alpine Global Management first reported a position in Revance Therapeutics, Inc. in Q4 2024 and held it in 1 quarter.
Alpine Global Management's Revance Therapeutics, Inc. position peaked at $74.2K in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Alpine Global Management's 13F filing for Q1 2025, filed 15 May 2025.